Publications
2024
Telomere length and DNA methylation epitype both provide independent prognostic information in CLL patients; data from the UK CLL4, ARCTIC and ADMIRE clinical trials.
Carr, L., Norris, K., Parker, H., Nilsson-Takeuchi, A., Bryant, D., Amarasinghe, H., . . . Strefford, J. C. (2024). Telomere length and DNA methylation epitype both provide independent prognostic information in CLL patients; data from the UK CLL4, ARCTIC and ADMIRE clinical trials.. British journal of haematology. doi:10.1111/bjh.19765
Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.
Lim, Y. J., Ward, V., Brown, A., Phillips, E., Kronsteiner, B., Malone, T., . . . Pettitt, A. (2024). Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.. British journal of haematology, 205(2), 440-451. doi:10.1111/bjh.19562
Consultations about randomised controlled trials are shorter and less in-depth for socioeconomically disadvantaged patients compared to socioeconomically advantaged patients: qualitative analysis across three trials.
Popa, M., Young, B., Rousseau, N., Cherry, M. G., Jenkins, I., Cloke, J., . . . Sherratt, F. C. (2024). Consultations about randomised controlled trials are shorter and less in-depth for socioeconomically disadvantaged patients compared to socioeconomically advantaged patients: qualitative analysis across three trials.. Trials, 25(1), 382. doi:10.1186/s13063-024-08216-4
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
Munir, T., Cairns, D. A., Bloor, A., Allsup, D., Cwynarski, K., Pettitt, A., . . . National Cancer Research Institute Chronic Lymphocytic Leukemia Subgroup. (2024). Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.. The New England journal of medicine, 390(4), 326-337. doi:10.1056/nejmoa2310063
2023
Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
Till, K. J., Abdullah, M., Alnassfan, T., Janet, G. Z., Marks, T., Coma, S., . . . Slupsky, J. R. (2023). Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib. SCIENTIFIC REPORTS, 13(1). doi:10.1038/s41598-023-30148-3
2022
Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study
Munir, T., Pitchford, A., Bloor, A., Pettitt, A., Patten, P. E. M., Forconi, F., . . . Hillmen, P. (2022). Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study. In BLOOD Vol. 140. doi:10.1182/blood-2022-170463
Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial
Kersten, M. J., Dreyling, M., Linton, K. M., Chitu, D., Tonino, S., Kap, M., . . . Zijlstra, J. M. (2022). Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial. In BLOOD Vol. 140 (pp. 2283-2285). doi:10.1182/blood-2022-156085
MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study
Munir, T., Cherrill, L. -R., Webster, N., Dalal, S., Boucher, R. H., Sankhalpara, C., . . . Hillmen, P. (2022). MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study. In BLOOD Vol. 140. doi:10.1182/blood-2022-166700
Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features
Robbe, P., Ridout, K. E., Vavoulis, D. V., Dreau, H., Kinnersley, B., Denny, N., . . . Schuh, A. (2022). Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features. NATURE GENETICS, 54(11), 1675-+. doi:10.1038/s41588-022-01211-y
COVID-19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta-analysis.
Lim, Y. J., Khan, U., Karpha, I., Ross, A., Saif, M., Remberger, M., . . . Floisand, Y. (2022). COVID-19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta-analysis.. EJHaem, 3(3), 862-872. doi:10.1002/jha2.465
Patient and health practitioner views and experiences of a cancer trial before and during COVID-19: qualitative study
Sherratt, F. C., Fisher, P., Mathieson, A., Cherry, M. G., Pettitt, A. R., & Young, B. (2022). Patient and health practitioner views and experiences of a cancer trial before and during COVID-19: qualitative study. TRIALS, 23(1). doi:10.1186/s13063-022-06453-z
Is it time for PET-guided therapy in follicular lymphoma?
Trotman, J., & Pettitt, A. R. (2022). Is it time for PET-guided therapy in follicular lymphoma?. BLOOD, 139(11), 1631-1641. doi:10.1182/blood.2020008243
Ibrutinib therapy related uveitis: A single-centre case series and literature review
Kalakonda, A. J. M., Jeffers, L., Wells, M., Pettitt, A., Kalakonda, N., Arumainathan, A., . . . Williams, S. (2022). Ibrutinib therapy related uveitis: A single-centre case series and literature review. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 197 (pp. 194). Retrieved from https://www.webofscience.com/
2021
Role of MYC and BCL2 expression in a cohort of 43 patients with DLBCL: a retrospective study
Khan, U. T., Kelly, M., Dodd, J., Fergiani, S., Hammer, B., Smith, J., . . . Menon, G. (2021). Role of MYC and BCL2 expression in a cohort of 43 patients with DLBCL: a retrospective study. JOURNAL OF CLINICAL PATHOLOGY, 74(12), 816-818. doi:10.1136/jclinpath-2020-207121
Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells
Linley, A. J., Karydis, L. I., Mondru, A. K., D'Avola, A., Al Shmrany, H., Cicconi, S., . . . Slupsky, J. R. (2021). Kinobead Profiling Reveals Reprogramming of BCR Signaling in Response to Therapy within Primary CLL Cells. CLINICAL CANCER RESEARCH, 27(20), 5647-5659. doi:10.1158/1078-0432.CCR-21-0161
Assessing technical and biological variation in SWATH-MS-based proteomic analysis of chronic lymphocytic leukaemia cells.
Eagle, G. L., Herbert, J. M. J., Zhuang, J., Oates, M., Khan, U. T., Kitteringham, N. R., . . . Falciani, F. (2021). Assessing technical and biological variation in SWATH-MS-based proteomic analysis of chronic lymphocytic leukaemia cells.. Scientific Reports, 11(1), 2932. doi:10.1038/s41598-021-82609-2
Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia
Lin, W. -Y., Fordham, S. E., Sunter, N., Elstob, C., Rahman, T., Willmore, E., . . . Allan, J. M. (2021). Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia. NATURE COMMUNICATIONS, 12(1). doi:10.1038/s41467-020-20822-9
Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort.
Bhogal, T., Khan, U. T., Lee, R., Stockdale, A., Hesford, C., Potti-Dhananjaya, V., . . . Palmieri, C. (2021). Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort.. Leukemia & lymphoma, 1-16. doi:10.1080/10428194.2021.1876865
Development of a cell-line model to mimic the pro-survival effect of nurse-like cells in chronic lymphocytic leukemia
Mohammad, I., Lin, K., Oates, M., Khan, U., Burger, J., Pettitt, A., & Zhuang, J. (n.d.). Development of a cell-line model to mimic the pro-survival effect of nurse-like cells in chronic lymphocytic leukemia. Leukemia and Lymphoma. doi:10.1080/10428194.2020.1811274
2020
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.
Pettitt, A. R., Jackson, R., Cicconi, S., Polydoros, F., Yap, C., Dodd, J., . . . Hillmen, P. (2020). Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.. Haematologica, 105(12), 2868-2871. doi:10.3324/haematol.2019.230805
A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial
Offner, F., Robak, T., Janssens, A., Babu, K. G., Kloczko, J., Grosicki, S., . . . Hillmen, P. (2020). A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial. BRITISH JOURNAL OF HAEMATOLOGY, 190(5), 736-740. doi:10.1111/bjh.16625
Hypertension and cardiovascular risk factors when treating cancer patients: underrecognised and undertreated
Essa, H., Pettitt, A. R., & Lip, G. Y. H. (2020). Hypertension and cardiovascular risk factors when treating cancer patients: underrecognised and undertreated. JOURNAL OF HUMAN HYPERTENSION. doi:10.1038/s41371-020-00400-8
Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial
Ghia, P., Coutre, S. E., Cheson, B. D., Barrientos, J. C., Hillmen, P., Pettitt, A. R., . . . Furman, R. R. (2020). Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial. HAEMATOLOGICA, 105(10), E519-E522. doi:10.3324/haematol.2019.238808
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial
Pettitt, A. R., Jackson, R., Cicconi, S., Polydoros, F., Yap, C., Dodd, J., . . . Hillmen, P. (2020). Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial. HAEMATOLOGICA, 105(12), 2868-2871. doi:10.3324/haematol.2019.230805
Clinico-biological significance of DNA methylation in chronic lymphocytic leukaemia patients: results from three UK clinical trials
Rose-Zerilli, M., Wojdacz, T., Amarasinghe, H., Kadalayil, L., Blakemore, S., Parker, H., . . . Strefford, J. (2020). Clinico-biological significance of DNA methylation in chronic lymphocytic leukaemia patients: results from three UK clinical trials. In LEUKEMIA & LYMPHOMA Vol. 61 (pp. 100-102). Retrieved from https://www.webofscience.com/
Comprehensive genomic testing for chronic lymphocytic leukaemia patients: WGS, one key to patient stratification
Ridout, K., Robbe, P., Cavalieri, D., Alsolami, R., Antoniou, P., Appleby, N., . . . Schuh, A. (2020). Comprehensive genomic testing for chronic lymphocytic leukaemia patients: WGS, one key to patient stratification. In LEUKEMIA & LYMPHOMA Vol. 61 (pp. 167-168). Retrieved from https://www.webofscience.com/
Ibrutinib plus venetoclax in Relapsed/Refractory CLL: The CLARITY Study
Munir, T., Rawstron, A., Brock, K., Munoz-Vicente, S., Yates, F., Bishop, R., . . . Hillmen, P. (2020). Ibrutinib plus venetoclax in Relapsed/Refractory CLL: The CLARITY Study. In LEUKEMIA & LYMPHOMA Vol. 61 (pp. 227-228). Retrieved from https://www.webofscience.com/
Mass cytometry analysis of B cell receptor signaling in normal B and chronic lymphocytic leukaemia cells in peripheral blood.
Yasin, F., Duckworth, A., Till, K., Pettitt, A., Lin, K., Kalakonda, N., & Slupsky, J. (2020). Mass cytometry analysis of B cell receptor signaling in normal B and chronic lymphocytic leukaemia cells in peripheral blood.. In LEUKEMIA & LYMPHOMA Vol. 61 (pp. 185-187). Retrieved from https://www.webofscience.com/
Resistance to venetoclax-induced apoptosis of CLL cells due to CD40 stimulation can be reversed by BCL-XL inhibition
Zhuang, J., Luckett, T., Cheng, X., Oates, M., Varadarajan, S., & Pettitt, A. (2020). Resistance to venetoclax-induced apoptosis of CLL cells due to CD40 stimulation can be reversed by BCL-XL inhibition. In LEUKEMIA & LYMPHOMA Vol. 61 (pp. 234-235). Retrieved from https://www.webofscience.com/
The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab
Kreuzer, K. -A., Furman, R. R., Stilgenbauer, S., Dubowy, R. L., Kim, Y., Munugalavadla, V., . . . Hallek, M. (2020). The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab. Leukemia, 34(1), 296-300. doi:10.1038/s41375-019-0533-6
Using signal-omics to fingerprint the impact of antigen engagement and therapy on BCR activation in CLL.
Linley, A., Kalakonda, N., Forconi, F., Pettitt, A., MacEwan, D., Packham, G., . . . Slupsky, J. (2020). Using signal-omics to fingerprint the impact of antigen engagement and therapy on BCR activation in CLL.. In LEUKEMIA & LYMPHOMA Vol. 61 (pp. 1-2). Retrieved from https://www.webofscience.com/
2019
40% of Females with Mantle Cell Lymphoma Are Managed with Initial Observation: Results from the MCL Biobank Observational Study
McCulloch, R., Smith, A., Wainman, B., Ingram, W., Lewis, A., Hawkins, M., . . . Rule, S. (2019). 40% of Females with Mantle Cell Lymphoma Are Managed with Initial Observation: Results from the MCL Biobank Observational Study. In BLOOD Vol. 134. doi:10.1182/blood-2019-128340
Multicentre Genome Wide Association Study Identifies Risk Alleles for Progressive Chronic Lymphocytic Leukaemia
Allsup, D., Lin, W. Y., Fordham, S. E., Sunter, N., Elstob, C., Rahman, T., . . . Allan, J. M. (2019). Multicentre Genome Wide Association Study Identifies Risk Alleles for Progressive Chronic Lymphocytic Leukaemia. In BLOOD Vol. 134. doi:10.1182/blood-2019-122037
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.
Hillmen, P., Rawstron, A. C., Brock, K., Muñoz-Vicente, S., Yates, F. J., Bishop, R., . . . Munir, T. (2019). Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.. Journal of Clinical Oncology, 37(30), 2722-2730. doi:10.1200/jco.19.00894
Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials.
Wojdacz, T. K., Amarasinghe, H. E., Kadalayil, L., Beattie, A., Forster, J., Blakemore, S. J., . . . Strefford, J. C. (2019). Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials. BLOOD ADVANCES, 3(16), 2474-2481. doi:10.1182/bloodadvances.2019000237
A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL
Eyre, T. A., Hildyard, C., Hamblin, A., Ali, A. S., Houlton, A., Hopkins, L., . . . Collins, G. P. (2019). A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL. HEMATOLOGICAL ONCOLOGY, 37(4), 352-359. doi:10.1002/hon.2662
POTENTIAL THERAPEUTIC ADVANTAGE FOR DUVELISIB IN MANTLE CELL LYMPHOMA: PI3Kδ AND OVEREXPRESSED PI3Kγ IN LYMPHOMA CELLS HAVE SPECIALIZED FUNCTIONAL ROLES
Till, K. J., Gallardo Zapata, J., Marks, T., Weaver, D. T., Pachter, J. A., Abdullah, M., . . . Slupsky, J. R. (2019). POTENTIAL THERAPEUTIC ADVANTAGE FOR DUVELISIB IN MANTLE CELL LYMPHOMA: PI3Kδ AND OVEREXPRESSED PI3Kγ IN LYMPHOMA CELLS HAVE SPECIALIZED FUNCTIONAL ROLES. In Hematological Oncology Vol. 37 (pp. 511-512). Wiley. doi:10.1002/hon.194_2631
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
Sharman, J. P., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., . . . Stilgenbauer, S. (2019). Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 37(16), 1391-1402. doi:10.1200/JCO.18.01460
Inactivated FABP5 suppresses malignant progression of prostate cancer cells by inhibiting the activation of nuclear fatty acid receptor PPARγ
Al-Jameel, W., Gou, X., Jin, X., Zhang, J., Wei, Q., Ai, J., . . . Ke, Y. (2019). Inactivated FABP5 suppresses malignant progression of prostate cancer cells by inhibiting the activation of nuclear fatty acid receptor PPARγ. Genes and Cancer, 10(3-4), 80-96. doi:10.18632/genesandcancer.192
Inactivated FABP5 suppresses malignant progression of prostate cancer cells by inhibiting the activation of nuclear fatty acid receptor PPARγ
Al-Jameel, W., Gou, X., Jin, X., Zhang, J., Wei, Q., Ai, J., . . . Ke, Y. (2019). Inactivated FABP5 suppresses malignant progression of prostate cancer cells by inhibiting the activation of nuclear fatty acid receptor PPARγ. Genes & Cancer, 10(3-4), 80-96. doi:10.18632/genesandcancer.192
Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL): Final analysis of the phase 3 COMPLEMENT 1 trial.
Offner, F., Robak, T., Janssens, A., Kanakasetty, G. B., Kloczko, J., Grosicki, S., . . . Hillmen, P. (2019). Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL): Final analysis of the phase 3 COMPLEMENT 1 trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37. Retrieved from https://www.webofscience.com/
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma
Flinn, I. W., Miller, C. B., Ardeshna, K. M., Tetreault, S., Assouline, S. E., Mayer, J., . . . Zinzani, P. L. (2019). DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 37(11), 912-+. doi:10.1200/JCO.18.00915
Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study
Munir, T., Rawstron, A., Brock, K., Vicente, S. M., Yates, F., Bishop, R., . . . Hillmen, P. (2019). Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 185 (pp. 25). Retrieved from https://www.webofscience.com/
Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with > 1 Year Prior Ibrutinib Exposure
Munir, T., Rawstron, A., Brock, K., Vicente, S. M., Yates, F., Bishop, R., . . . Hillmen, P. (2019). Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with > 1 Year Prior Ibrutinib Exposure. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 185 (pp. 85-86). Retrieved from https://www.webofscience.com/
2018
Highly Comprehensive Genomic Testing for CLL: WGS, One Key to CLL Patient Stratification
Ridout, K. E., Robbe, P., Cavalieri, D., Becq, J., He, M., Clifford, R., . . . Schuh, A. (2018). Highly Comprehensive Genomic Testing for CLL: WGS, One Key to CLL Patient Stratification. In BLOOD Vol. 132. doi:10.1182/blood-2018-99-115935
Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study
Hillmen, P., Rawstron, A., Brock, K., Vicente, S. M., Yates, F., Bishop, R., . . . Munir, T. (2018). Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study. In BLOOD Vol. 132. doi:10.1182/blood-2018-182
Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with >1 Year Prior Ibrutinib Exposure
Rawstron, A., Munir, T., Brock, K., Webster, N., Vicente, S. M., Yates, F., . . . Hillmen, P. (2018). Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with >1 Year Prior Ibrutinib Exposure. In BLOOD Vol. 132. doi:10.1182/blood-2018-181
Population Based Observational Study Demonstrates Significant Increase in Watch-and-Wait for Newly Diagnosed Mantle Cell Lymphoma
McCulloch, R., Berrow, M., Wainman, B., Crosbie, N., Pettitt, A., & Rule, S. (2018). Population Based Observational Study Demonstrates Significant Increase in Watch-and-Wait for Newly Diagnosed Mantle Cell Lymphoma. In BLOOD Vol. 132. doi:10.1182/blood-2018-99-114528
Central nervous system plasmablastic lymphoma evolving from polyclonal plasmacytosis
Khan, U. T., Racu-Amoasii, I., Arumainathan, A., Meswani, U., Pettitt, A. R., & Menon, G. (2018). Central nervous system plasmablastic lymphoma evolving from polyclonal plasmacytosis. BRITISH JOURNAL OF HAEMATOLOGY, 183(3), 345. doi:10.1111/bjh.15489
A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma
Pratt, G., Yap, C., Oldreive, C., Slade, D., Bishop, R., Griffiths, M., . . . Stankovic, T. (2018). A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. BRITISH JOURNAL OF HAEMATOLOGY, 182(3), 429-433. doi:10.1111/bjh.14793
Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline
Schuh, A. H., Parry-Jones, N., Appleby, N., Bloor, A., Dearden, C. E., Fegan, C., . . . Hillmen, P. (2018). Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline. BRITISH JOURNAL OF HAEMATOLOGY, 182(3), 344-359. doi:10.1111/bjh.15460
LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia
Gohil, S. H., Maciocia, N., Patrick, P., Roberts, T., Counsell, N., Smith, P., . . . Nathwani, A. C. (2018). LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia. LEUKEMIA & LYMPHOMA, 59(7), 1730-1733. doi:10.1080/10428194.2017.1399311
The clinical importance of DNA methylation signatures in chronic lymphocytic leukemia patients treated with chemo-immunotherapy
Wojdacz, T. K., Amarasinghe, H. E., Rose-Zerilli, M. J. J., Beattie, A., Forster, J., Kadalayil, L., . . . Strefford, J. C. (2018). The clinical importance of DNA methylation signatures in chronic lymphocytic leukemia patients treated with chemo-immunotherapy. In CANCER RESEARCH Vol. 78. doi:10.1158/1538-7445.AM2018-3306
An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects.
Alharthi, A., Beck, D., Howard, D. R., Hillmen, P., Oates, M., Pettitt, A., & Wagner, S. D. (2018). An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects.. BMC research notes, 11(1), 280. doi:10.1186/s13104-018-3391-9
Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD eradication after 6 months of combination therapy
Munir, T., Rawstron, A., Brock, K., Vicente, S. M., Yates, F., Bishop, R., . . . Hillmen, P. (2018). Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD eradication after 6 months of combination therapy. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 181 (pp. 34-35). Retrieved from https://www.webofscience.com/
Patients with a Memory-like DNA Methylation Signature exhibit long-term survival after first-line immuno-chemotherapy: Data from the UK CLL4, ARCTIC and ADMIRE trials
Amarasinghe, H., Wojdacz, T., Rose-Zerilli, M., Beattie, A., Forster, J., Kadalayil, L., . . . Strefford, J. (2018). Patients with a Memory-like DNA Methylation Signature exhibit long-term survival after first-line immuno-chemotherapy: Data from the UK CLL4, ARCTIC and ADMIRE trials. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 181 (pp. 29). Retrieved from https://www.webofscience.com/
Whole genome sequencing in the clinic identifies CLL patients with high risk of relapse: pilot study for the 100,000 Genomes Project
Robbe, P., Ridout, K., Becq, J., He, M., Clifford, R., Burns, A., . . . Schuh, A. (2018). Whole genome sequencing in the clinic identifies CLL patients with high risk of relapse: pilot study for the 100,000 Genomes Project. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 181 (pp. 28). Retrieved from https://www.webofscience.com/
2017
Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome
Till, K. J., Allen, J. C., Talab, F., Lin, K., Allsup, D., Cawkwell, L., . . . Slupsky, J. R. (2017). Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome. SCIENTIFIC REPORTS, 7. doi:10.1038/s41598-017-17021-w
Linking genotype to clinical phenotype through proteomic analysis of CLL trial samples
Eagle, G., Zhuang, J., Oates, M., Kitteringham, N., Herbert, J., Falciani, F., . . . Hillmen, P. (2017). Linking genotype to clinical phenotype through proteomic analysis of CLL trial samples. In LEUKEMIA & LYMPHOMA Vol. 58 (pp. 100-101). Retrieved from https://www.webofscience.com/
Use of differentiated THP. 1 cells to mimic nurse-like cells for its pro-survival effect on chronic lymphocytic leukaemia cells
Mohammad, I. S., Zhuang, J., Pettitt, A., Oates, M., & Lin, K. (2017). Use of differentiated THP. 1 cells to mimic nurse-like cells for its pro-survival effect on chronic lymphocytic leukaemia cells. In LEUKEMIA & LYMPHOMA Vol. 58 (pp. 102-104). Retrieved from https://www.webofscience.com/
Delineating the distinct role of AKT in mediating cell survival and proliferation induced by CD154 and IL-4/IL-21 in chronic lymphocytic leukemia
Chapman, E. A., Oates, M., Mohammad, I. S., Davies, B. R., Stockman, P. K., Zhuang, J., & Pettitt, A. R. (2017). Delineating the distinct role of AKT in mediating cell survival and proliferation induced by CD154 and IL-4/IL-21 in chronic lymphocytic leukemia. Oncotarget, 8(61), 102948-102964. doi:10.18632/oncotarget.22292
Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL
Munir, T., Howard, D. R., McParland, L., Pocock, C., Rawstron, A. C., Hockaday, A., . . . Hillmen, P. (2017). Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL. LEUKEMIA, 31(10), 2085-2093. doi:10.1038/leu.2017.65
Optimising Technical Protocols to Detect AID Expression in Archived FFPE Samples of Patients with Follicular Lymphoma
Alishlash, O., Lin, K., Coupland, S., Oates, M., Kalirai, H., & Pettitt, A. (2017). Optimising Technical Protocols to Detect AID Expression in Archived FFPE Samples of Patients with Follicular Lymphoma. In JOURNAL OF PATHOLOGY Vol. 241 (pp. S11). Retrieved from https://www.webofscience.com/
Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia
Law, P. J., Berndt, S. I., Speedy, H. E., Camp, N. J., Sava, G. P., Skibola, C. F., . . . Slager, S. (2017). Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nature Communications, 8. doi:10.1038/ncomms14175
Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci
Law, P. J., Sud, A., Mitchell, J. S., Henrion, M., Orlando, G., Lenive, O., . . . Houlston, R. S. (2017). Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci. SCIENTIFIC REPORTS, 7. doi:10.1038/srep41071
A IBRUTINIB RESULTS IN REDUCTION OF PHOSPHORYLATION OF MULTIPLE KINASES IN THE B-CELL RECEPTOR PATHWAY IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): RESULTS OF THE BLOODWISE TAP ICICLLE STUDY
Munir, T., Rawstron, A., Munoz-Vicente, S., Brock, K., Yates, F., Bishop, R., . . . Hillmen, P. (2017). A IBRUTINIB RESULTS IN REDUCTION OF PHOSPHORYLATION OF MULTIPLE KINASES IN THE B-CELL RECEPTOR PATHWAY IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): RESULTS OF THE BLOODWISE TAP ICICLLE STUDY. In HAEMATOLOGICA Vol. 102 (pp. 229-230). Retrieved from https://www.webofscience.com/
A phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma
Stankovic, T., Yap, C., Oldreive, C., Slade, D., Bishop, R., Griffiths, M., . . . Devereux, S. (2017). A phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma. In LEUKEMIA & LYMPHOMA Vol. 58 (pp. 110-111). Retrieved from https://www.webofscience.com/
ADDING OBINUTUZUMAB TO IBRUTINIB ENHANCES DEPLETION OF CLL CELLS IN PERIPHERAL BLOOD AND BONE MARROW AFTER 1 & 6 MONTHS COMBINED THERAPY INITIAL RESULTS FROM THE BLOODWISE TAP ICICLLE EXTENSION STUDY
Rawstron, A., Munir, T., Munoz-Vicente, S., Brock, K., Yates, F., Bishop, R., . . . Hillmen, P. (2017). ADDING OBINUTUZUMAB TO IBRUTINIB ENHANCES DEPLETION OF CLL CELLS IN PERIPHERAL BLOOD AND BONE MARROW AFTER 1 & 6 MONTHS COMBINED THERAPY INITIAL RESULTS FROM THE BLOODWISE TAP ICICLLE EXTENSION STUDY. In HAEMATOLOGICA Vol. 102 (pp. 69). Retrieved from https://www.webofscience.com/
Addition of obinutuzumab to ibrutinib enhances depletion of CLL cells in the peripheral blood and bone marrow after 1 month & 6 months of combination therapy: initial results from the bloodwise TAP IcICLLe extension study
Rawstron, A., Munir, T., Munoz-Vicente, S., Brock, K., Yates, F., Bishop, R., . . . Hillmen, P. (2017). Addition of obinutuzumab to ibrutinib enhances depletion of CLL cells in the peripheral blood and bone marrow after 1 month & 6 months of combination therapy: initial results from the bloodwise TAP IcICLLe extension study. In LEUKEMIA & LYMPHOMA Vol. 58 (pp. 233-234). Retrieved from https://www.webofscience.com/
DYNAMO: A PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY FOLLICULAR LYMPHOMA
Zinzani, P. L., Wagner-Johnston, N., Miller, C., Ardeshna, K., Tertreault, S., Assouline, S., . . . Flinn, I. (2017). DYNAMO: A PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY FOLLICULAR LYMPHOMA. In HAEMATOLOGICA Vol. 102 (pp. 315). Retrieved from https://www.webofscience.com/
Improved overall survival of relapsed chronic lymphocytic leukemia (CLL) patients exhibiting a complex karyotype and treated with idelalisib plus rituximab
Kreuzer, K. -A., Furman, R., Stilgenbauer, S., Dubowy, R., Kim, Y., Munugalavadla, V., . . . Hallek, M. (2017). Improved overall survival of relapsed chronic lymphocytic leukemia (CLL) patients exhibiting a complex karyotype and treated with idelalisib plus rituximab. In LEUKEMIA & LYMPHOMA Vol. 58 (pp. 167-168). Retrieved from https://www.webofscience.com/
2016
Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Iciclle Extension Study
Rawstron, A. C., Munir, T., Munoz-Vicente, S., Brock, K., Yates, F. J., Bishop, R., . . . Hillmen, P. (2016). Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Iciclle Extension Study. In BLOOD Vol. 128. doi:10.1182/blood.V128.22.2049.2049
Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma
Flinn, I. W., Miller, C. B., Ardeshna, K. M., Tetreault, S., Assouline, S. E., Zinzani, P. L., . . . Wagner-Johnston, N. D. (2016). Dynamo: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Relapsed Refractory Indolent Non-Hodgkin Lymphoma. In BLOOD Vol. 128. doi:10.1182/blood.V128.22.1218.1218
Identifying High-Risk CLL to Predict Early Relapse after FCR Based Treatment Using Whole Genome Sequencing: First Results from the Genomics England CLL Pilot
Robbe, P., Ridout, K., Becq, J., He, M., Clifford, R., Alsolami, R., . . . Schuh, A. (2016). Identifying High-Risk CLL to Predict Early Relapse after FCR Based Treatment Using Whole Genome Sequencing: First Results from the Genomics England CLL Pilot. In BLOOD Vol. 128. doi:10.1182/blood.V128.22.2022.2022
Outcome of Patients with Complex Karyotype in a Phase 3 Randomized Study of Idelalisib Plus Rituximab for Relapsed Chronic Lymphocytic Leukemia
Kreuzer, K. -A., Furman, R. R., Stilgenbauer, S., Dubowy, R. L., Kim, Y., Munugalavadla, V., . . . Hallek, M. (2016). Outcome of Patients with Complex Karyotype in a Phase 3 Randomized Study of Idelalisib Plus Rituximab for Relapsed Chronic Lymphocytic Leukemia. In BLOOD Vol. 128. doi:10.1182/blood.V128.22.192.192
Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia
Rose-Zerilli, M. J. J., Parker, H., Larrayoz, M., Clifford, R., Blakemore, S., Edelmann, J., . . . Strefford, J. C. (2015). Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia. In BLOOD Vol. 126. Retrieved from https://www.webofscience.com/
Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia
Parker, H., Rose-Zerilli, M. J. J., Larrayoz, M., Clifford, R., Edelmann, J., Blakemore, S., . . . Strefford, J. C. (2016). Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia. Leukemia, 30, 2179-2186. doi:10.1038/leu.2016.134
NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome
Eyre, T. A., Clifford, R., Bloor, A., Boyle, L., Roberts, C., Cabes, M., . . . Schuh, A. (2016). NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome. BRITISH JOURNAL OF HAEMATOLOGY, 175(1), 43-54. doi:10.1111/bjh.14177
Longitudinal bioimpedance assessments to evaluate hydration in POEMS syndrome
Nwosu, A. C., Morris, L., Mayland, C., Mason, S., Pettitt, A., & Ellershaw, J. (2016). Longitudinal bioimpedance assessments to evaluate hydration in POEMS syndrome. BMJ SUPPORTIVE & PALLIATIVE CARE, 6(3), 369-372. doi:10.1136/bmjspcare-2015-000991
FINAL RESULTS OF THE NCRI CLL210 TRIAL OF ALEMTUZUMAB, DEXAMETHASONE AND LENALIDOMIDE IN PATIENTS WITH HIGH-RISK CLL (ORIGINAL PROTOCOL)
Pettitt, A. R., Polydoros, F., Dodd, J., Oates, M., Lin, K., Kalakonda, N., . . . Hillmen, P. (2016). FINAL RESULTS OF THE NCRI CLL210 TRIAL OF ALEMTUZUMAB, DEXAMETHASONE AND LENALIDOMIDE IN PATIENTS WITH HIGH-RISK CLL (ORIGINAL PROTOCOL). In HAEMATOLOGICA Vol. 101 (pp. 726). Retrieved from https://www.webofscience.com/
LINKING PROTEOME AND GENOME FOR BIOMARKER DISCOVERY IN CLL-ESTABLISHMENT OF A CLL PROTEIN DATABASE
Eagle, G. L., Zhuang, J., Jenkins, R., Kitteringham, N., Oates, M., Park, K., . . . Pettitt, A. (2016). LINKING PROTEOME AND GENOME FOR BIOMARKER DISCOVERY IN CLL-ESTABLISHMENT OF A CLL PROTEIN DATABASE. In HAEMATOLOGICA Vol. 101 (pp. 420-421). Retrieved from https://www.webofscience.com/
Outcomes of patients with relapsed and refractory chronic lynnphocytic leukemia (CLL) who discontinue idelalisib treatment.
Brown, J. R., Ghia, P., Jones, J. A., Pettitt, A., Sharman, J. P., Ysebaert, L., . . . Furman, R. R. (2016). Outcomes of patients with relapsed and refractory chronic lynnphocytic leukemia (CLL) who discontinue idelalisib treatment.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34. doi:10.1200/JCO.2016.34.15_suppl.7531
A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study
Rawstron, A. C., Fazi, C., Agathangelidis, A., Villamor, N., Letestu, R., Nomdedeu, J., . . . CLL, E. R. I. C. E. R. I. (2016). A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia, 30, 929-936. doi:10.1038/leu.2015.313
BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells
Butterworth, M., Pettitt, A., Varadarajan, S., & Cohen, G. M. (2016). BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells. BRITISH JOURNAL OF CANCER, 114(6), 638-641. doi:10.1038/bjc.2016.49
Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus (vol 10, e0142379, 2015)
Hargreaves, C. E., Iriyama, C., Rose-Zerilli, M. J. J., Nagelkerke, S. Q., Hussain, K., Ganderton, R., . . . Strefford, J. C. (2016). Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus (vol 10, e0142379, 2015). PLOS ONE, 11(3). doi:10.1371/journal.pone.0145040
DISCONTINUATION OF IDELALISIB TREATMENT DUE TO DISEASE PROGRESSION IN PATIENTS WITH RELAPSED AND REFRACTORY CLL: AN EVALUATION OF OUTCOMES
Brown, J. R., Ghia, P., Jones, J. A., Pettitt, A. R., Sharman, J. P., Ysebaert, L., . . . Stilgenbauer, S. (2016). DISCONTINUATION OF IDELALISIB TREATMENT DUE TO DISEASE PROGRESSION IN PATIENTS WITH RELAPSED AND REFRACTORY CLL: AN EVALUATION OF OUTCOMES. In HAEMATOLOGICA Vol. 101 (pp. 54). Retrieved from https://www.webofscience.com/
2015
Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus
Hargreaves, C. E., Iriyama, C., Rose-Zerilli, M. J. J., Nagelkerke, S. Q., Hussain, K., Ganderton, R., . . . Strefford, J. C. (2015). Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus. PLOS ONE, 10(11). doi:10.1371/journal.pone.0142379
Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL
Guieze, R., Robbe, P., Clifford, R., de Guibert, S., Pereira, B., Timbs, A., . . . Schuh, A. (2015). Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. BLOOD, 126(18), 2110-2117. doi:10.1182/blood-2015-05-647578
Second Interim Analysis of a Phase 3 Study Evaluating Idelalisib and Rituximab for Relapsed Chronic Lymphocytic Leukemia
Pagel, J. M., Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Hillmen, P., . . . Hallek, M. J. (2015). Second Interim Analysis of a Phase 3 Study Evaluating Idelalisib and Rituximab for Relapsed Chronic Lymphocytic Leukemia. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 15, S201-S202. doi:10.1016/j.clml.2015.04.062
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial
Hillmen, P., Robak, T., Janssens, A., Babu, K. G., Kloczko, J., Grosicki, S., . . . Investigators, C. O. M. P. L. E. M. E. N. T. 1. S. (2015). Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. The Lancet, 385(9980), 1873-1883. doi:10.1016/S0140-6736(15)60027-7
Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin's lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1phosphate receptors and integrins
Middle, S., Coupland, S. E., Taktak, A., Kidgell, V., Slupsky, J. R., Pettitt, A. R., & Till, K. J. (2015). Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin's lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1phosphate receptors and integrins. EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 4. doi:10.1186/s40164-015-0004-3
Total Proteome Analysis Identifies Migration Defects as a Major Pathogenetic Factor in Immunoglobulin Heavy Chain Variable Region (IGHV)-unmutated Chronic Lymphocytic Leukemia
Eagle, G., Zhuang, J., Jenkins, R., Till, K., Jithesh, P., Lin, K., . . . Pettitt, A. (2015). Total Proteome Analysis Identifies Migration Defects as a Major Pathogenetic Factor in Immunoglobulin Heavy Chain Variable Region (IGHV)-unmutated Chronic Lymphocytic Leukemia. Molecular and Cellular Proteomics, 14(4), 933-945. doi:10.1074/mcp.M114.044479
Common variation at 12q24.13 (<i>OAS3</i>) influences chronic lymphocytic leukemia risk
Sava, G. P., Speedy, H. E., Di Bernardo, M. C., Dyer, M. J. S., Holroyd, A., Sunter, N. J., . . . Houlston, R. S. (2015). Common variation at 12q24.13 (<i>OAS3</i>) influences chronic lymphocytic leukemia risk. LEUKEMIA, 29(3), 748-751. doi:10.1038/leu.2014.311
Expression of Functional Sphingosine-1 Phosphate Receptor-1 Is Reduced by B Cell Receptor Signaling and Increased by Inhibition of PI3 Kinase δ but Not SYK or BTK in Chronic Lymphocytic Leukemia Cells
Till, K. J., Pettitt, A., & Slupsky, J. (2015). Expression of Functional Sphingosine-1 Phosphate Receptor-1 Is Reduced by B Cell Receptor Signaling and Increased by Inhibition of PI3 Kinase δ but Not SYK or BTK in Chronic Lymphocytic Leukemia Cells. Journal of Immunology, 194(5), 2439-2446. doi:10.4049/jimmunol.1402304
A LONGITUDINAL STUDY OF NEXT GENERATION SEQUENCING IN CHRONIC LYMPHOCYTIC LEUKEMIA SHOWS EVIDENCE OF CHEMOTHERAPY-INDUCED MUTAGENESIS AND SNOWBALLING EFFECT DUE TO LOSS OF P53/ATM-MEDIATED DNA REPAIR
Karim, S., Johnson, G., Pettitt, A., & Lin, K. (2015). A LONGITUDINAL STUDY OF NEXT GENERATION SEQUENCING IN CHRONIC LYMPHOCYTIC LEUKEMIA SHOWS EVIDENCE OF CHEMOTHERAPY-INDUCED MUTAGENESIS AND SNOWBALLING EFFECT DUE TO LOSS OF P53/ATM-MEDIATED DNA REPAIR. In HAEMATOLOGICA Vol. 100 (pp. 222-223). Retrieved from https://www.webofscience.com/
Distinct requirement of AKT for CD40-induced cell growth and division in chronic lymphocytic leukemia
Zhuang, J., Chapman, E., Stockman, P., Davies, B., & Pettitt, A. (2015). Distinct requirement of AKT for CD40-induced cell growth and division in chronic lymphocytic leukemia. LEUKEMIA & LYMPHOMA, 56, 16-18. Retrieved from https://www.webofscience.com/
Health-related quality of life impact of idelalisib in patients with relapsed chronic lymphocytic leukemia (CLL): phase 3 results
Munir, T., Hillmen, P., Eradat, H., Ghia, P., O'Brien, S., Furman, R., . . . Wagner, L. (2015). Health-related quality of life impact of idelalisib in patients with relapsed chronic lymphocytic leukemia (CLL): phase 3 results. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 169 (pp. 53). Retrieved from https://www.webofscience.com/
Next-generation sequencing in chronic lymphocytic leukaemia using Ion Torrent PGM shows evidence of chemotherapy-induced mutagenesis and a snowballing effect due to loss of p53/ATM-mediated DNA repair
Karim, S., Johnson, G., Pettitt, A., & Lin, K. (2015). Next-generation sequencing in chronic lymphocytic leukaemia using Ion Torrent PGM shows evidence of chemotherapy-induced mutagenesis and a snowballing effect due to loss of p53/ATM-mediated DNA repair. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 169 (pp. 73). Retrieved from https://www.webofscience.com/
OPTIMISATION OF RNA EXTRACTION AND RT-QPCR FOR THE QUANTIFICATION OF AID IN ARCHIVED FFPE BIOPSY SAMPLES: ONLY TWO SECTIONS OF 4 MM TISSUE ARE REQUIRED
Alishlash, O., Pettitt, A., Coupland, S., & Lin, K. (2015). OPTIMISATION OF RNA EXTRACTION AND RT-QPCR FOR THE QUANTIFICATION OF AID IN ARCHIVED FFPE BIOPSY SAMPLES: ONLY TWO SECTIONS OF 4 MM TISSUE ARE REQUIRED. In HAEMATOLOGICA Vol. 100 (pp. 765). Retrieved from https://www.webofscience.com/
Optimisation of RNA extraction and RT-qPCR for the quantification of AID in archived FFPE biopsy samples: only two sections of 4 μm tissue are required
Alishlash, O., Coupland, S., Pettitt, A., & Lin, K. (2015). Optimisation of RNA extraction and RT-qPCR for the quantification of AID in archived FFPE biopsy samples: only two sections of 4 μm tissue are required. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 169 (pp. 74-75). Retrieved from https://www.webofscience.com/
Physical examination and MRD assessment rather than CT-scans is effective to assess responses in patients treated with fludarabine-based chemoimmunotherapy. Analysis of patients in the UK NCRI ADMIRE and ARCTIC trials
Munir, T., Cohen, D., Pocock, C., Rawstron, A., Collet, L., McParland, L., . . . Hillmen, P. (2015). Physical examination and MRD assessment rather than CT-scans is effective to assess responses in patients treated with fludarabine-based chemoimmunotherapy. Analysis of patients in the UK NCRI ADMIRE and ARCTIC trials. LEUKEMIA & LYMPHOMA, 56, 26-27. Retrieved from https://www.webofscience.com/
SINGLE ARM NCRI FEASIBILITY PHASE II STUDY OF CHOP IN COMBINATION WITH OFATUMUMAB IN INDUCTION AND MAINTENANCE FOR PATIENTS WITH NEWLY DIAGNOSED RICHTER'S SYNDROME
Eyre, T., Clifford, R., Bloor, A., Boyle, L., Cabes, M., Collins, G., . . . Schuh, A. (2015). SINGLE ARM NCRI FEASIBILITY PHASE II STUDY OF CHOP IN COMBINATION WITH OFATUMUMAB IN INDUCTION AND MAINTENANCE FOR PATIENTS WITH NEWLY DIAGNOSED RICHTER'S SYNDROME. In HAEMATOLOGICA Vol. 100 (pp. 109). Retrieved from https://www.webofscience.com/
2014
A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study
Rawstron, A., Fazi, C., Villamor, N., Delgado, J., Letestu, R., Cymbalista, F., . . . Ghia, P. (2014). A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study. BLOOD, 124(21). Retrieved from https://www.webofscience.com/
Genomic Dissection of the Fcγ Receptor Region in the Context of Monoclonal Antibody Therapy
Hargreaves, C., Iriyama, C., Rose-Zerilli, M. J. J., Lee, C., Potter, K., Ganderton, R., . . . Strefford, J. C. (2014). Genomic Dissection of the Fcγ Receptor Region in the Context of Monoclonal Antibody Therapy. BLOOD, 124(21). Retrieved from https://www.webofscience.com/
Mutational Landscape of 118 Relapsed Chronic Lymphocytic Leukemia Clinical Trial Samples; Evidence for a Multiple-Hit Profile Using Targeted Next Generation Sequencing
Robbe, P., Guieze, R., Clifford, R. M., de Guibert, S., Timbs, A., Dilhuydy, M. -S., . . . Tournilhac, O. (2014). Mutational Landscape of 118 Relapsed Chronic Lymphocytic Leukemia Clinical Trial Samples; Evidence for a Multiple-Hit Profile Using Targeted Next Generation Sequencing. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/
The Identification of Further Minimal Regions of Overlap in Chronic Lymphocytic Leukemia Using High-Resolution SNP Arrays
Knight, S. J. L., Clifford, R., Robbe, P., Ramos, S. D. C., Burns, A., Timbs, A. T., . . . Shuh, A. (2014). The Identification of Further Minimal Regions of Overlap in Chronic Lymphocytic Leukemia Using High-Resolution SNP Arrays. BLOOD, 124(21). Retrieved from https://www.webofscience.com/
Total Proteome Analysis Identifies Migration Defects As a Major Pathogenetic Factor in IGHV-Unmutated Chronic Lymphocytic Leukemia
Eagle, G. L., Jenkins, R. E., Till, K. J., Puthen, J., Lin, K., Johnson, G. G., . . . Pettitt, A. R. (2014). Total Proteome Analysis Identifies Migration Defects As a Major Pathogenetic Factor in IGHV-Unmutated Chronic Lymphocytic Leukemia. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/
Towards Response Prediction Using Integrated Genomics in Chronic Lymphocytic Leukaemia: Results on 250 First-Line FCR Treated Patients from UK Clinical Trials
Clifford, R. M., Robbe, P., Weller, S., Timbs, A. T., Titsias, M., Burns, A., . . . Schuh, A. (2014). Towards Response Prediction Using Integrated Genomics in Chronic Lymphocytic Leukaemia: Results on 250 First-Line FCR Treated Patients from UK Clinical Trials. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/
Selective IAP inhibition results in sensitization of unstimulated but not CD40‐stimulated chronic lymphocytic leukaemia cells to TRAIL‐induced apoptosis
Zhuang, J., Laing, N., Oates, M., Lin, K., Johnson, G., & Pettitt, A. R. (2014). Selective IAP inhibition results in sensitization of unstimulated but not CD40‐stimulated chronic lymphocytic leukaemia cells to TRAIL‐induced apoptosis. Pharmacology Research & Perspectives, 2(6). doi:10.1002/prp2.81
Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach
te Raa, G. D., Malcikova, J., Mraz, M., Trbusek, M., Le Garff-Tavernier, M., Merle-Beral, H., . . . Kater, A. P. (2014). Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach. BRITISH JOURNAL OF HAEMATOLOGY, 167(4), 565-569. doi:10.1111/bjh.13006
Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia
Lin, K., Farahani, M., Yang, Y., Johnson, G. G., Oates, M., Atherton, M., . . . Pettitt, A. R. (2014). Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 167(3), 346-355. doi:10.1111/bjh.13043
Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results.
Ghia, P., O'Brien, S. M., Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., . . . Wagner, L. I. (2014). Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32. doi:10.1200/jco.2014.32.15_suppl.7099
Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL.
Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., Hillmen, P., . . . Hallek, M. J. (2014). Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32. doi:10.1200/jco.2014.32.15_suppl.7012
Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study
Hillmen, P., Gribben, J. G., Follows, G. A., Milligan, D., Sayala, H. A., Moreton, P., . . . Pocock, C. F. E. (2014). Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study. Journal of Clinical Oncology, 32(12), 1236-1241. doi:10.1200/JCO.2013.49.6547
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., . . . O'Brien, S. M. (2014). Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine, 370, 997-1007. doi:10.1056/NEJMoa1315226
SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage
Clifford, R., Louis, T., Robbe, P., Ackroyd, S., Burns, A., Timbs, A. T., . . . Schuh, A. (2014). SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. BLOOD, 123(7), 1021-1031. doi:10.1182/blood-2013-04-490847
EBV-associated post-transplant lymphoproliferative disorder following <i>in vivo</i> T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era
Fox, C. P., Burns, D., Parker, A. N., Peggs, K. S., Harvey, C. M., Natarajan, S., . . . Chaganti, S. (2014). EBV-associated post-transplant lymphoproliferative disorder following <i>in vivo</i> T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era. BONE MARROW TRANSPLANTATION, 49(2), 280-286. doi:10.1038/bmt.2013.170
2nd analysis of a phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Idelalisib and Rituximab for previously treated patients with chronic lymphocytic leukemia
Hallek, M., Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., . . . Kroenig, H. (2014). 2nd analysis of a phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Idelalisib and Rituximab for previously treated patients with chronic lymphocytic leukemia. ONCOLOGY RESEARCH AND TREATMENT, 37, 183. Retrieved from https://www.webofscience.com/
A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia
Speedy, H. E., Di Bernardo, M. C., Sava, G. P., Dyer, M. J. S., Holroyd, A., Wang, Y., . . . Houlston, R. S. (2014). A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. NATURE GENETICS, 46(01), 56-60. doi:10.1038/ng.2843
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib and rituximab for previously treated patients with chronic lymphocytic leukaemia (CLL) (NCRN375)
Hillmen, P., Furman, R., Sharmann, J., Coutre, S., Cheson, B., Pagel, J., . . . O'Brien, S. (2014). A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib and rituximab for previously treated patients with chronic lymphocytic leukaemia (CLL) (NCRN375). In BRITISH JOURNAL OF HAEMATOLOGY Vol. 165 (pp. 3). Retrieved from https://www.webofscience.com/
COMPARISON OF GEMCITABINE <i>VS</i>. NON-GEMCITABINE BASED SALVAGE CHEMOTHERAPY IN RELAPSED/REFRACTORY AGGRESSIVE LYMPHOMA
Taylor, D., Angelillo, P., Ward, C., Collins, D., Salim, R., Pettitt, A., . . . Kalakonda, N. (2014). COMPARISON OF GEMCITABINE <i>VS</i>. NON-GEMCITABINE BASED SALVAGE CHEMOTHERAPY IN RELAPSED/REFRACTORY AGGRESSIVE LYMPHOMA. In HAEMATOLOGICA Vol. 99 (pp. 701). Retrieved from https://www.webofscience.com/
HEALTH-RELATED QUALITY OF LIFE IMPACT OF IDELALISIB (IDELA) IN PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PHASE 3 RESULTS
Eradat, H. A., Ghia, P., O'Brien, S. M., Hillmen, P., Furman, R. R., Coutre, S. E., . . . Wagner, L. I. (2014). HEALTH-RELATED QUALITY OF LIFE IMPACT OF IDELALISIB (IDELA) IN PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PHASE 3 RESULTS. In HAEMATOLOGICA Vol. 99 (pp. 63). Retrieved from https://www.webofscience.com/
Motility and trafficking in B-cell non-Hodgkin's lymphoma (Review)
Till, K. J., Coupland, S. E., & Pettitt, A. R. (2014). Motility and trafficking in B-cell non-Hodgkin's lymphoma (Review). INTERNATIONAL JOURNAL OF ONCOLOGY, 45(1), 5-12. doi:10.3892/ijo.2014.2395
ORAL FCR INDUCES HIGHER COMPLETE REMISSION RATES AND MRD NEGATIVITY IN UNTREATED CLL THAN PREVIOUS REPORTS OF INTRAVENOUS THERAPY: COMBINED RESULTS OF THE NCRI ADMIRE AND ARCTIC TRIALS
Munir, T., Cohen, D., Pocock, C., Rawstron, A., McParland, L., Chalmers, A., . . . Hillmen, P. (2014). ORAL FCR INDUCES HIGHER COMPLETE REMISSION RATES AND MRD NEGATIVITY IN UNTREATED CLL THAN PREVIOUS REPORTS OF INTRAVENOUS THERAPY: COMBINED RESULTS OF THE NCRI ADMIRE AND ARCTIC TRIALS. In HAEMATOLOGICA Vol. 99 (pp. 54). Retrieved from https://www.webofscience.com/
Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted)
Hillmen, P., Pettitt, A., Schuh, A., Milligan, D., Bowles, K., Bareford, D., . . . McKeown, A. (2014). Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted). In BRITISH JOURNAL OF HAEMATOLOGY Vol. 165 (pp. 19-20). Retrieved from https://www.webofscience.com/
PRE-TREATMENT WITH IDELALISIB MARKEDLY REDUCES RITUXIMAB INFUSION-RELATED REACTIONS AND INFUSION INTERRUPTIONS IN PATIENTS WITH CLL
Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., Pagel, J. M., Barrientos, J. C., . . . Cheson, B. D. (2014). PRE-TREATMENT WITH IDELALISIB MARKEDLY REDUCES RITUXIMAB INFUSION-RELATED REACTIONS AND INFUSION INTERRUPTIONS IN PATIENTS WITH CLL. In HAEMATOLOGICA Vol. 99 (pp. 55). Retrieved from https://www.webofscience.com/
Pharmacogenetics in the treatment of chronic lymphocytic leukemia: what does the future hold?
Johnson, G. G., Carr, D. F., Pirmohamed, M., & Pettitt, A. R. (2014). Pharmacogenetics in the treatment of chronic lymphocytic leukemia: what does the future hold?. PHARMACOGENOMICS, 15(7), 897-900. doi:10.2217/pgs.14.60
Pre-treatment with Idelalisib markedly reduces Rituximab infusion-related reactions and infusion interruptions in patients with CLL
Hallek, M., Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., Pagel, J. M., . . . Schuster, A. (2014). Pre-treatment with Idelalisib markedly reduces Rituximab infusion-related reactions and infusion interruptions in patients with CLL. ONCOLOGY RESEARCH AND TREATMENT, 37, 52-53. Retrieved from https://www.webofscience.com/
Results of the randomised phase II NCRI ADMIRE trial of FC-R and FCM-R in previously untreated CLL: oral FCR is highly effective and safe but the addition of mitoxantrone does not improve responses
Bloor, A. J. C., Cohen, D., Pocock, C., Rawstron, A., McParland, L., Chalmers, A., . . . Hillmen, P. (2014). Results of the randomised phase II NCRI ADMIRE trial of FC-R and FCM-R in previously untreated CLL: oral FCR is highly effective and safe but the addition of mitoxantrone does not improve responses. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 165 (pp. 18). Retrieved from https://www.webofscience.com/
SECOND INTERIM ANALYSIS OF A PHASE 3 STUDY EVALUATING IDELALISIB AND RITUXIMAB FOR RELAPSED CLL
Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., Hillmen, P., . . . Hallek, M. J. (2014). SECOND INTERIM ANALYSIS OF A PHASE 3 STUDY EVALUATING IDELALISIB AND RITUXIMAB FOR RELAPSED CLL. In HAEMATOLOGICA Vol. 99 (pp. 249-250). Retrieved from https://www.webofscience.com/
Targeting Cell Metabolism In Chronic Lymphocytic Leukaemia (CLL); A Viable Therapeutic Approach?
E. Clapham, C., R. Pettitt, A., & R. Slupsky, J. (n.d.). Targeting Cell Metabolism In Chronic Lymphocytic Leukaemia (CLL); A Viable Therapeutic Approach?. Journal of Hematology And Oncology Research, 1(1), 7-23. doi:10.14302/issn.2372-6601.jhor-13-346
2013
<i>CYP2B6</i>*<i>6</i> is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia
Johnson, G. G., Lin, K., Cox, T. F., Oates, M., Sibson, D. R., Eccles, R., . . . Pettitt, A. R. (2013). <i>CYP2B6</i>*<i>6</i> is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia. BLOOD, 122(26), 4253-4258. doi:10.1182/blood-2013-07-516666
CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia
Johnson, G. G., Lin, K., Cox, T. F., Oates, M., Sibson, D. R., Eccles, R., . . . Pettitt, A. R. (2013). CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia. Blood, 122(26), 4253-4258. doi:10.1182/blood-2013-07-516666
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., . . . O'Brien, S. M. (2013). A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL). In BLOOD Vol. 122. doi:10.1182/blood.V122.21.LBA-6.LBA-6
Chemokine unresponsiveness of chronic lymphocytic leukemia cells results from impaired endosomal recycling of Rap1 and is associated with a distinctive type of immunological anergy.
Pye, D. S., Rubio, I., Pusch, R., Lin, K., Pettitt, A. R., & Till, K. J. (2013). Chemokine unresponsiveness of chronic lymphocytic leukemia cells results from impaired endosomal recycling of Rap1 and is associated with a distinctive type of immunological anergy.. Journal of immunology (Baltimore, Md. : 1950), 191(3), 1496-1504. doi:10.4049/jimmunol.1203484
Abstracts of the 53rd Annual Scientific Meeting of the British Society for Haematology. April 15-17, 2013. Liverpool, United Kingdom.
Abstracts of the 53rd Annual Scientific Meeting of the British Society for Haematology. April 15-17, 2013. Liverpool, United Kingdom. (2013). British journal of haematology, 161 Suppl 1, 1-87. doi:10.1111/bjh.12263
2012
Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak
Melarangi, T., Zhuang, J., Lin, K., Rockliffe, N., Bosanquet, A. G., Oates, M., . . . Pettitt, A. R. (2012). Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak. CELL DEATH & DISEASE, 3. doi:10.1038/cddis.2012.102
Functional Analysis of the ATM-p53-p21 Pathway in the LRF CLL4 Trial: Blockade at the Level of p21 Is Associated with Short Response Duration
Lin, K., Adamson, J., Johnson, G. G., Carter, A., Oates, M., Wade, R., . . . Pettitt, A. R. (2012). Functional Analysis of the ATM-p53-p21 Pathway in the LRF CLL4 Trial: Blockade at the Level of p21 Is Associated with Short Response Duration. CLINICAL CANCER RESEARCH, 18(15), 4191-4200. doi:10.1158/1078-0432.CCR-11-2936
Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of <i>TP53</i>: Final Results of the National Cancer Research Institute CLL206 Trial
Pettitt, A. R., Jackson, R., Carruthers, S., Dodd, J., Dodd, S., Oates, M., . . . Hillmen, P. (2012). Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of <i>TP53</i>: Final Results of the National Cancer Research Institute CLL206 Trial. JOURNAL OF CLINICAL ONCOLOGY, 30(14), 1647-1655. doi:10.1200/JCO.2011.35.9695
Advances in the understanding of the mechanisms of glucocorticoid sensitivity and resistance in lymphoid malignancies
Zhuang, J., & Pettitt, A. R. (2012). Advances in the understanding of the mechanisms of glucocorticoid sensitivity and resistance in lymphoid malignancies. Current Topics in Steroid Research, 9, 93-109.
The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes in chromosome 17p
Lin, K., Lane, B., Carter, A., Johnson, G. G., Onwuazor, O., Oates, M., . . . Pettitt, A. R. (2012). The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes in chromosome 17p. British Journal of Haematology.
2011
Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p
Arumainathan, A., Kalakonda, N., & Pettitt, A. R. (2011). Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p. EUROPEAN JOURNAL OF HAEMATOLOGY, 87(4), 372-375. doi:10.1111/j.1600-0609.2011.01667.x
A randomised Phase II Trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia
Hillmen, P., Cohen, D., Cocks, K., Pettitt, A. R., Sayala, H., Rawstrom, A., . . . Pocock, C. (2011). A randomised Phase II Trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. British Journal of Haematology, 152(5), 570-578.
Incurable, Invisible and Inconclusive: Watchful Waiting for Chronic Lymphocytic Leukaemia and Implications for Doctor-Patient Communication
Evans, J., Ziebland, S., & Pettitt, A. R. (2011). Incurable, Invisible and Inconclusive: Watchful Waiting for Chronic Lymphocytic Leukaemia and Implications for Doctor-Patient Communication. European Journal of Cancer Care, 1365-2354.
2010
TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations.
Zenz, T., Vollmer, D., Trbusek, M., Smardova, J., Benner, A., Soussi, T., . . . European Research Initiative on CLL (ERIC). (2010). TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations.. Leukemia, 24(12), 2072-2079. doi:10.1038/leu.2010.208
Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.
Chakraverty, R., Orti, G., Roughton, M., Shen, J., Fielding, A., Kottaridis, P., . . . Mackinnon, S. (2010). Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.. Blood, 116(16), 3080-3088. doi:10.1182/blood-2010-05-286856
Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk.
Crowther-Swanepoel, D., Broderick, P., Di Bernardo, M. C., Dobbins, S. E., Torres, M., Mansouri, M., . . . Houlston, R. S. (2010). Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk.. Nature genetics, 42(2), 132-136. doi:10.1038/ng.510
Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition
Zhuang, J., Hawkins, S. F., Glenn, M. A., Lin, K., Johnson, G. G., Carter, A., . . . Pettitt, A. R. (2010). Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95(1), 110-118. doi:10.3324/haematol.2009.010272
Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition
Zhuang, J., Hawkins, S. F., Glenn, M. A., Lin, K., Johnson, G. G., Carter, A., . . . Pettitt, A. R. (2010). Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95(1), 110-118. doi:10.3324/haematol.2009.010272
Ribosome-associated nucleophosmin 1: increased expression and shuttling activity distinguishes prognostic subtypes in chronic lymphocytic leukaemia
Rees-Unwin, K. S., Faragher, R., Unwin, R. D., Adams, J., Brown, P. J., Buckle, A. M., . . . Burthem, J. (2010). Ribosome-associated nucleophosmin 1: increased expression and shuttling activity distinguishes prognostic subtypes in chronic lymphocytic leukaemia. British Journal of Haematology, 148(4), 534-543.
Variant <i>IRF4/MUM1</i> associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia
Allan, J. M., Sunter, N. J., Bailey, J. R., Pettitt, A. R., Harris, R. J., Pepper, C., . . . Allsup, D. J. (2010). Variant <i>IRF4/MUM1</i> associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia. LEUKEMIA, 24(4), 877-881. doi:10.1038/leu.2009.298
p53 dysfunction in chronic lymphocytic leukemia
Pospisilova, S., & Pettitt, A. R. (2010). p53 dysfunction in chronic lymphocytic leukemia. In K. Stamatopoulos, P. Ghia, & R. Rosenquist (Eds.), New Biological Prognostic Markers in Chronic Lymphocytic Leukemia (pp. 73-95). Italy: Walter Kluyers Health Ltd.
2009
Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.
Hoskin, P. J., Lowry, L., Horwich, A., Jack, A., Mead, B., Hancock, B. W., . . . Johnson, P. W. M. (2009). Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27(32), 5390-5396. doi:10.1200/jco.2009.23.3239
A Novel Type of p53 Pathway Dysfunction in Chronic Lymphocytic Leukemia Resulting from Two Interacting Single Nucleotide Polymorphisms within the <i>p21</i> Gene
Johnson, G. G., Sherrington, P. D., Carter, A., Lin, K., Liloglou, T., Field, J. K., & Pettitt, A. R. (2009). A Novel Type of p53 Pathway Dysfunction in Chronic Lymphocytic Leukemia Resulting from Two Interacting Single Nucleotide Polymorphisms within the <i>p21</i> Gene. CANCER RESEARCH, 69(12), 5210-5217. doi:10.1158/0008-5472.CAN-09-0627
Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy.
Faderl, S., Ferrajoli, A., Frankfurt, O., & Pettitt, A. (2009). Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy.. Leukemia, 23(3), 457-466. doi:10.1038/leu.2008.322
Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome.
Robinson, S. P., Sureda, A., Canals, C., Russell, N., Caballero, D., Bacigalupo, A., . . . Lymphoma Working Party of the EBMT. (2009). Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome.. Haematologica, 94(2), 230-238. doi:10.3324/haematol.13441
Results of the phase II NCRI CLL206 trial of alemtuzumab in combination with high-dose methylprednisolone for high-risk (17p-) CLL
Pettitt, A. R., Matutes, E., Dearden, C., Oscier, D. G., Carruthers, S., Dodd, S., . . . Hillmen, P. (2009). Results of the phase II NCRI CLL206 trial of alemtuzumab in combination with high-dose methylprednisolone for high-risk (17p-) CLL. Hematologica, 94, 351a.
2008
A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia.
Di Bernardo, M. C., Crowther-Swanepoel, D., Broderick, P., Webb, E., Sellick, G., Wild, R., . . . Houlston, R. S. (2008). A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia.. Nature genetics, 40(10), 1204-1210. doi:10.1038/ng.219
DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia
Willmore, E., Elliott, S. L., Mainou-Fowler, T., Summerfield, G. R., Jackson, G. H., O'Neill, F., . . . Durkacz, B. W. (2008). DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia. CLINICAL CANCER RESEARCH, 14(12), 3984-3992. doi:10.1158/1078-0432.CCR-07-5158
Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells.
Lin, K., Rockliffe, N., Johnson, G. G., Sherrington, P. D., & Pettitt, A. R. (2008). Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells.. Oncogene, 27(17), 2445-2455. doi:10.1038/sj.onc.1210893
Glucocorticoid-based combination therapy for chronic lymphotic leukemia: new tricks for an old dog.
Pettitt, A. R. (2008). Glucocorticoid-based combination therapy for chronic lymphotic leukemia: new tricks for an old dog.. Leukemia & lymphoma, 49(10), 1843-1845. doi:10.1080/10428190802455883
2007
The development of sarcoidosis with the use of alemtuzumab - clues to T-cell immune reconstitution.
Thachil, J., Jadhav, V., Gautam, M., McKew, S., Arumainathan, A., Collins, D., . . . Pettitt, A. (2007). The development of sarcoidosis with the use of alemtuzumab - clues to T-cell immune reconstitution.. British journal of haematology, 138(4), 559-560. doi:10.1111/j.1365-2141.2007.06687.x
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.
Catovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M., Bezares, R. F., . . . NCRI Chronic Lymphocytic Leukaemia Working Group. (2007). Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.. Lancet (London, England), 370(9583), 230-239. doi:10.1016/s0140-6736(07)61125-8
The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia
Kay, N. E., O'Brien, S. M., Pettitt, A. R., & Stilgenbauer, S. (2007). The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. LEUKEMIA, 21(9), 1885-1891. doi:10.1038/sj.leu.2404802
2006
Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects.
Pettitt, A. R., Matutes, E., & Oscier, D. (2006). Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects.. Leukemia, 20(8), 1441-1445. doi:10.1038/sj.leu.2404265
Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia.
Carter, A., Lin, K., Sherrington, P. D., Atherton, M., Pearson, K., Douglas, A., . . . Pettitt, A. R. (2006). Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia.. Leukemia, 20(4), 737-740. doi:10.1038/sj.leu.2404120
2005
Basic fibroblast growth factor suppresses p53 activation in the neoplastic cells of a proportion of patients with chronic lymphocytic leukaemia.
Romanov, V. V., James, C. H., Sherrington, P. D., & Pettitt, A. R. (2005). Basic fibroblast growth factor suppresses p53 activation in the neoplastic cells of a proportion of patients with chronic lymphocytic leukaemia.. Oncogene, 24(45), 6855-6860. doi:10.1038/sj.onc.1208895
Analysis of VH gene sequences using two web-based immunogenetics resources gives different results, but the affinity maturation status of chronic lymphocytic leukaemia clones as assessed from either of the resulting data sets has no prognostic significance.
Lane, B. S., Mensah, A. A., Lin, K., Pettitt, A. R., & Sherrington, P. D. (2005). Analysis of VH gene sequences using two web-based immunogenetics resources gives different results, but the affinity maturation status of chronic lymphocytic leukaemia clones as assessed from either of the resulting data sets has no prognostic significance.. Leukemia, 19(5), 741-749. doi:10.1038/sj.leu.2403720
2004
Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia.
Carter, A., Lin, K., Sherrington, P. D., & Pettitt, A. R. (2004). Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia.. British journal of haematology, 127(4), 425-428. doi:10.1111/j.1365-2141.2004.05223.x
Down-regulation of BCL-2 and its prevention by interleukin-4 in cultured chronic lymphocytic leukaemia cells is a methodological artefact caused by failure of protein detection/extraction following the onset of cell death.
Kamiguti, A. S., Moran, E. C., & Pettitt, A. R. (2004). Down-regulation of BCL-2 and its prevention by interleukin-4 in cultured chronic lymphocytic leukaemia cells is a methodological artefact caused by failure of protein detection/extraction following the onset of cell death.. British journal of haematology, 127(2), 236-238. doi:10.1111/j.1365-2141.2004.05184.x
The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes.
Jones, G. G., Reaper, P. M., Pettitt, A. R., & Sherrington, P. D. (2004). The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes.. Oncogene, 23(10), 1911-1921. doi:10.1038/sj.onc.1207318
Natural history of CLL: Current thinking
Pettitt, A. R., Sherrington, P., Allsup, D. J., Matrai, Z., Cawley, J. C., & Zuzel, M. (2004). Natural history of CLL: Current thinking. In A. Miles (Ed.), UK Key Advances in Clinical Practice Series. Key Advances in the Effective Management of Chronic Lymphocytic Leukaemia (pp. not known at present). not known at present: not known at present.
2003
High frequency of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia patients using the VH3-21 gene segment.
Lin, K., Manocha, S., Harris, R. J., Matrai, Z., Sherrington, P. D., & Pettitt, A. R. (2003). High frequency of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia patients using the VH3-21 gene segment.. Blood, 102(3), 1145-1146. doi:10.1182/blood-2003-04-1289
Mechanism of action of purine analogues in chronic lymphocytic leukaemia.
Pettitt, A. R. (2003). Mechanism of action of purine analogues in chronic lymphocytic leukaemia.. British journal of haematology, 121(5), 692-702. doi:10.1046/j.1365-2141.2003.04336.x
Correlation between cell size and CD38 expression in chronic lymphocytic leukaemia.
Manocha, S., Matrai, Z., Osthoff, M., Carter, A., & Pettitt, A. R. (2003). Correlation between cell size and CD38 expression in chronic lymphocytic leukaemia.. Leukemia & lymphoma, 44(5), 797-800. doi:10.1080/1042819031000068034
2002
Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia.
Lin, K., Sherrington, P. D., Dennis, M., Matrai, Z., Cawley, J. C., & Pettitt, A. R. (2002). Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia.. Blood, 100(4), 1404-1409. doi:10.1182/blood-2001-11-0066
Response of hairy cells to IFN-α involves induction of apoptosis through autocrine TNF-α and protection by adhesion
Baker, P. K., Pettitt, A. R., Slupsky, J. R., Chen, H. J., Glenn, M. A., Zuzel, M., & Cawley, J. C. (2002). Response of hairy cells to IFN-α involves induction of apoptosis through autocrine TNF-α and protection by adhesion. BLOOD, 100(2), 647-653. doi:10.1182/blood.V100.2.647
Cytoprotective antioxidant activity of serum albumin and autocrine catalase in
Moran, E. C., Kamiguti, A. S., Cawley, J. C., & Pettitt, A. R. (2002). Cytoprotective antioxidant activity of serum albumin and autocrine catalase in. Br J Haematol., 116(2), 316-328.
Response of hairy cells to IFN-alpha involves induction of apoptosis through autocrine TNF-alpha and protection by adhesion
Baker, P. K., Pettitt, A. R., Slupsky, J. R., Chen, H. J., Glenn, M. A., Zuzel, M., & Cawley, J. C. (2002). Response of hairy cells to IFN-alpha involves induction of apoptosis through autocrine TNF-alpha and protection by adhesion. Blood, 100(2), 647-653.
2001
Homotypic interactions protect chronic lymphocytic leukaemia cells from spontaneous death in vitro.
Pettitt, A. R., Moran, E. C., & Cawley, J. C. (2001). Homotypic interactions protect chronic lymphocytic leukaemia cells from spontaneous death in vitro.. Leukemia research, 25(11), 1003-1012. doi:10.1016/s0145-2126(01)00067-4
p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation.
Pettitt, A. R., Sherrington, P. D., Stewart, G., Cawley, J. C., Taylor, A. M., & Stankovic, T. (2001). p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation.. Blood, 98(3), 814-822. doi:10.1182/blood.v98.3.814
CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia.
Matrai, Z., Lin, K., Dennis, M., Sherrington, P., Zuzel, M., Pettitt, A. R., & Cawley, J. C. (2001). CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia.. Blood, 97(6), 1902-1903.
2000
Caspases influence the mode but not the extent of cell death induced by purine analogues in chronic lymphocytic leukaemia.
Pettitt, A. R., & Cawley, J. C. (2000). Caspases influence the mode but not the extent of cell death induced by purine analogues in chronic lymphocytic leukaemia.. British journal of haematology, 109(4), 800-804. doi:10.1046/j.1365-2141.2000.02068.x
Granulocyte-macrophage colony-stimulating factor as an autocrine survival factor for mature normal and malignant B lymphocytes.
Harris, R. J., Pettitt, A. R., Schmutz, C., Sherrington, P. D., Zuzel, M., Cawley, J. C., & Griffiths, S. D. (2000). Granulocyte-macrophage colony-stimulating factor as an autocrine survival factor for mature normal and malignant B lymphocytes.. Journal of immunology (Baltimore, Md. : 1950), 164(7), 3887-3893. doi:10.4049/jimmunol.164.7.3887
Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues.
Pettitt, A. R., Sherrington, P. D., & Cawley, J. C. (2000). Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues.. Cancer Res., 60(15), 4187-4193.
1999
The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia.
Pettitt, A. R., Sherrington, P. D., & Cawley, J. C. (1999). The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia.. British journal of haematology, 106(4), 1049-1051. doi:10.1046/j.1365-2141.1999.01649.x
Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms.
Pettitt, A. R., Clarke, A. R., Cawley, J. C., & Griffiths, S. D. (1999). Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms.. British journal of haematology, 105(4), 986-988. doi:10.1046/j.1365-2141.1999.01448.x
Hairy-cell leukaemia: biology and management.
Pettitt, A. R., Zuzel, M., & Cawley, J. C. (1999). Hairy-cell leukaemia: biology and management.. Br J Haematol., 106(1), 2-8.
1995
An assessment of the Coulter VCS automated differential counter scatterplots in the recognition of specific acute leukaemia variants.
Pettitt, A. R., Grace, P., & Chu, P. (1995). An assessment of the Coulter VCS automated differential counter scatterplots in the recognition of specific acute leukaemia variants.. Clin Lab Haematol., 17(2), 125-129.
1994
Thrombotic microangiopathy following bone marrow transplantation.
Pettitt, A. R., & Clark, R. E. (1994). Thrombotic microangiopathy following bone marrow transplantation.. Bone marrow transplantation, 14(4), 495-504.
Vogt-Koyanagi-Harada syndrome complicating allogeneic bone marrow transplantation.
Pettitt, A. R., Neoh, C., Wong, S. H., & Clark, R. E. (1994). Vogt-Koyanagi-Harada syndrome complicating allogeneic bone marrow transplantation.. Bone marrow transplantation, 13(2), 225-227.